Herpes News and Research

RSS

Herpes is an infection caused by two different but closely related viruses — herpes simplex virus type 1 (HSV-1) or cold sores and herpes simplex virus type 2 (HSV-2) or genital herpes. Both are easy to catch. They have similar symptoms (blisters or sores) and both can occur on different parts of the body. When the infection is on the mouth, it is called oral herpes. When it is on or near the sex organs, it is called genital herpes. There is no cure for herpes. Treatments are available to speed up the healing of the genital sores.

Profectus BioSciences to conduct proof-of-concept studies with its rVSV vector technology

Profectus BioSciences, Inc. (Profectus), a clinical stage biopharmaceutical company focused on the development of novel vaccine candidates for serious chronic infections, announced today it has entered into a research collaboration agreement with the PATH Malaria Vaccine Initiative (MVI) to conduct proof-of-concept studies with its proprietary, recombinant vesicular stomatitis virus (rVSV) vector technology as a preventative malaria vaccine.

26 Aug 2009

The SaniGuard dry-on-contact sanitising spray is launched by MisterSterile.com

A sanitising spray that kills 99.99% of Viruses, Bacteria and Germs is now available for purchase in the UK. The SaniGuard wipes, spray and fogger products were invented by David Morgan, president of DEM Technology in the United States. After patenting the product he was awarded EPA registration for its use on food contact surfaces in 1996.

25 Aug 2009

Thyretain TSI Reporter BioAssay test for detecting auto-antibodies attains the FDA clearance

Diagnostic HYBRIDS announces the FDA clearance, for marketing under the 510(k) pre-notification process, of the Thyretain TSI Reporter BioAssay. Thyretain is an in vitro diagnostic use test that specifically detects auto-antibodies called thyroid stimulating immunoglobulins (TSI) in patient serum.

25 Aug 2009

Retigabine's Phase IIa clinical trial preliminary results announced

Valeant Pharmaceuticals International today announced preliminary results from its Phase IIa proof-of-concept clinical trial of retigabine for the treatment of pain associated with postherpetic neuralgia (PHN), a painful and common complication of shingles.

24 Aug 2009

Nanoviricides herpes study discussed on CBS News report

NanoViricides, Inc. (OTC BB: NNVC.OB), reported today that the CBS affiliate TV station WBRZ interviewed Professor K. Gus Kousoulas , PhD, in which he explained the potential implications of the Company’s nanoviricides™ anti-Herpes drug candidates.

12 Aug 2009

Inhibitex reports Q2 2009 financials

Inhibitex, Inc. (Nasdaq: INHX), today announced its financial results for the second quarter ended June 30, 2009. The Company held cash, cash equivalents and short-term investments of $24.5 million at June 30, 2009, as compared to $33.1 million at December 31, 2008.

12 Aug 2009

Nanoviricides anti-herpes drug candidate reduces viral load by 99.99%

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), has announced that the herpes simplex viral load was reduced by 99.99% or 10,000 fold in in-vitro studies by nanoviricides™ drug candidates.

10 Aug 2009

New kind of “molecular condom” to protect women from AIDS

University of Utah scientists developed a new kind of “molecular condom” to protect women from AIDS in Africa and other impoverished areas. Before sex, women would insert a vaginal gel that turns semisolid in the presence of semen, trapping AIDS virus particles in a microscopic mesh so they can’t infect vaginal cells.

10 Aug 2009

New research helps explain why treated genital herpes sores boost risk of HIV infection

New research helps explain why infection with herpes simplex virus-2 (HSV-2), which causes genital herpes, increases the risk for HIV infection even after successful treatment heals the genital skin sores and breaks that often result from HSV-2.

3 Aug 2009

US FDA approves Lipsovir for cold sores

The US Food and Drug Administration (FDA) has now approved Lipsovir, i.e. granted Medivir's New Drug Application (NDA) for the use of acyclovir and hydrocortisone for early treatment of recurrent cold sores to decreases the risk of cold sores, and to shorten the healing time for those cold sores which are not prevented.

3 Aug 2009

Cytomegalovirus may cause high blood pressure

A new study suggests for the first time that cytomegalovirus (CMV), a common viral infection affecting between 60 and 99 percent of adults worldwide, is a cause of high blood pressure, a leading risk factor for heart disease, stroke and kidney disease.

15 May 2009

Herpes drug Acyclovir does not reduce risk of HIV transmission, does slow HIV progression, study says

The drug acyclovir, which suppresses herpes simplex virus-2, does not reduce the risk of HIV transmission when taken by HIV-positive people who also have herpes, according to a study conducted by researchers at the University of Washington, United Press International reports.

14 May 2009

Births by Cesarean section rose by more than 40 percent in 10 years

The percentage of pregnant women undergoing a repeat Cesarean section (C-section) delivery jumped from 65 percent to 90 percent between 1997 and 2006, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

16 Apr 2009

Immune cells in skin fight off infection better than the rest

Scientists at the University of Melbourne have discovered the local action of immune cells in the skin, which could improve treatment of viral skin infections.

8 Apr 2009

Male circumcision reduces men's risk of contracting HPV, herpes, study says

Male circumcision can reduce a man's risk of contracting the sexually transmitted infections human papillomavirus and herpes, according to a study published this week in the New England Journal of Medicine, the Wall Street Journal reports.

30 Mar 2009

Male circumcision reduces men's risk of contracting HPV, herpes, study says

30 Mar 2009

Discovery of protein that reactivates latent herpes simplex virus

Research in Public Library of Science (PLoS) Pathogens appears to solve a long standing medical mystery by identifying a viral protein, VP16, as the molecular key that prompts herpes simplex virus (HSV) to exit latency and cause recurrent disease.

29 Mar 2009

Male circumcision reduces risk of herpes simplex virus type 2 and human papillomavirus

Heterosexual men who undergo medical circumcision can significantly reduce their risk of acquiring two common sexually transmitted infections - herpes simplex virus type 2 (HSV-2), the cause of genital herpes, and human papillomavirus (HPV), which can cause cancer and genital warts, according to a report in the March 26 issue of the New England Journal of Medicine (NEJM).

26 Mar 2009

Discovery of cellular process that fights type 1 herpes simplex

Scientists have discovered a new way for our immune system to combat the elusive virus responsible for cold sores: Type 1 herpes simplex (HSV-1).

23 Mar 2009

Sirion Therapeutics sNDA for Durezol to treat uveitis accepted for FDA review

Sirion Therapeutics, Inc. announced today that its supplemental New Drug Application (sNDA) submitted to the U.S. Food and Drug Administration (FDA) seeking market approval of Durezol(TM) (difluprednate ophthalmic emulsion) 0.05% to treat endogenous anterior uveitis has been accepted for review.

16 Mar 2009